EPO and hepatocellular carcinoma: In this study, the PCD-related gene signature developed by integrating MCM2, SPP1, S100A9, MSC and EPO provided a risk stratification for HCC patients, and HCC patients with high risk were found to be more sensitive to Cisplatin and 5.Fluorouracil.